Search Results
Sep 08, 2026, 07:00 ET Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
Sept. 8, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management
More news about: Compugen Ltd.
Aug 03, 2026, 07:00 ET Compugen Reports Second Quarter 2026 Results
2029HOLON, Israel, Aug. 3, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today reported financial
More news about: Compugen Ltd.
Jul 21, 2026, 07:00 ET Compugen to Participate in BTIG Biotechnology Conference 2026
July 21, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management
More news about: Compugen Ltd.
Jul 20, 2026, 07:00 ET Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026
July 20, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the
More news about: Compugen Ltd.
Jun 18, 2026, 07:00 ET Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress
June 18, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today presented a trial-in-progress
More news about: Compugen Ltd.
Jun 11, 2026, 07:00 ET Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026
June 11, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced
More news about: Compugen Ltd.
Jun 08, 2026, 07:00 ET Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development
June 8, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management
More news about: Compugen Ltd.
May 18, 2026, 07:00 ET Compugen Reports First Quarter 2026 Results
May 18, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today reported financial results
More news about: Compugen Ltd.
May 12, 2026, 07:00 ET Compugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum
May 12, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management
More news about: Compugen Ltd.
May 04, 2026, 07:00 ET Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026
May 4, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the
More news about: Compugen Ltd.
Apr 09, 2026, 07:00 ET Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference
April 9, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present at
More news about: Compugen Ltd.
Mar 03, 2026, 11:03 ET SPECTRUM BUSINESS EXPANDS TECHNOLOGY OFFERINGS FOR CALIFORNIA STATE AGENCIES THROUGH CALNET CONTRACT
for today's distributed workforce.Spectrum Business now provides fiber connectivity directly into the California Government Enterprise Network (CGEN) data center. This allows agencies to better manage data traffic through Spectrum Business equipment that businesses don't need to own or maintain."Spectrum
More news about: Charter Communications, Inc.
Mar 02, 2026, 07:00 ET Compugen Reports Fourth Quarter and Full Year 2025 Results
March 2, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today reported financial results
More news about: Compugen Ltd.
Feb 19, 2026, 07:00 ET Compugen to Participate in Upcoming Investor Conferences
Feb. 19, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that management
More news about: Compugen Ltd.
Feb 17, 2026, 07:00 ET Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026
Feb. 17, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the
More news about: Compugen Ltd.
Feb 12, 2026, 07:00 ET Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors
Feb. 12, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced the appointment
More news about: Compugen Ltd.
Dec 17, 2025, 07:00 ET Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
Dec. 17, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, today announced that
More news about: Compugen Ltd.
Nov 10, 2025, 07:00 ET Compugen Reports Third Quarter 2025 Results
Nov. 10, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, today reported financial
More news about: Compugen Ltd.
Nov 04, 2025, 07:00 ET Compugen to Participate in Stifel 2025 Healthcare Conference
Nov. 4, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced
More news about: Compugen Ltd.
Oct 27, 2025, 07:00 ET Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025
Oct. 27, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced
More news about: Compugen Ltd.
Oct 13, 2025, 07:00 ET Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025
Oct. 13, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, today announced that
More news about: Compugen Ltd.
Oct 06, 2025, 07:00 ET Compugen to Present at SITC 2025
Oct. 6, 2025 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery, powered by AI/ML today announced, that
More news about: Compugen Ltd.